Global Sepsis Diagnostics Industry Trends and Market Forecast 2026–2030
Uncover key drivers, emerging technologies, and competitive movements shaping the sepsis diagnostics market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Sepsis Diagnostics Market from 2026 to 2030?
The sepsis diagnostics market has experienced significant expansion in recent years. It is anticipated to expand from $1.07 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. This historical market growth can be attributed to an increase in hospital-acquired infections, the integration of rapid diagnostic tests, various regulatory approvals, improvements in advanced lab infrastructure, and heightened clinical awareness.
The sepsis diagnostics market is anticipated to experience substantial expansion over the coming years. By 2030, this market is projected to reach $1.57 billion, exhibiting a compound annual growth rate (CAGR) of 7.9%. Drivers for this growth during the forecast period include AI-powered diagnostic platforms, the broadening of biomarker-based testing, the incorporation of tele-diagnostics, innovative assays for sepsis detection, and the rise of point-of-care diagnostics. Key trends for the upcoming period encompass point-of-care diagnostic devices, biomarker-based tests, rapid blood culture kits, AI-assisted diagnostic platforms, and their integration with hospital IT systems.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23514&type=smp
What Drivers Are Affecting Demand In The Sepsis Diagnostics Market?
The increasing occurrence of hospital-acquired infections is anticipated to boost the growth of the sepsis diagnostics market moving forward. Hospital-acquired infections (HAIs) are characterized as infections that manifest during or after a patient’s stay in a healthcare facility, typically 48 hours or more following admission, and were not present at the time of entry. This escalating incidence of hospital-acquired infections is linked to a rise in antibiotic resistance. The excessive and improper use of antibiotics in healthcare environments has fostered the development of resistant bacteria, rendering infections more difficult to treat. Sepsis diagnostics aids in the early detection of hospital-acquired infections by pinpointing pathogens and biomarkers, thereby enabling prompt treatment and mitigating complications. For instance, in November 2024, as per the Australian Institute of Health and Welfare, an Australia-based government agency, during 2022–23, HACs were noted in 2% of public hospital admissions and 0.8% of private hospital admissions, with healthcare-associated infections emerging as the most frequent complication. Consequently, the rising incidence of hospital-acquired infections acts as a key driver for expansion in the sepsis diagnostics market.
Which Segment Groups Are Influencing The Sepsis Diagnostics Market?
The sepsis diagnostics market covered in this report is segmented –
1) By Product: Instruments, Blood Culture Media, Assay Kits And Reagents, Software
2) By Technology: Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Other Technologies
3) By Pathogen: Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, Other Pathogens
4) By Method: Automated Diagnostics, Conventional Diagnostics
5) By End-Users: Hospitals And Clinics, Pathology And Reference Laboratories, Research Institutes
Subsegments:
1) By Instruments: Automated Analyzers, Point-Of-Care (PoC) Testing Devices, Microfluidic-Based Devices, Polymerase Chain Reaction (PCR) Instruments, Flow Cytometers
2) By Blood Culture Media: Aerobic Blood Culture Media, Anaerobic Blood Culture Media, Mycobacteria Blood Culture Media, Pediatric Blood Culture Media, Fungal Blood Culture Media
3) By Assay Kits And Reagents: Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Polymerase Chain Reaction (PCR) Assay Kits, Immunoassay Reagents, Molecular Diagnostic Reagents, Biosensor-Based Assay Kits
4) By Software: Data Management Software, Laboratory Information Systems (LIS), Artificial Intelligence (AI)-Based Diagnostic Tools, Predictive Analytics Software, Cloud-Based Diagnostic Platforms
What Upcoming Trends Are Likely To Define The Future Path Of The Sepsis Diagnostics Market?
Leading companies in the sepsis diagnostics market are concentrating on developing innovative approaches, such as culture-free diagnostic solutions, to enable quick and accurate detection of sepsis without relying on traditional blood cultures. A culture-free diagnostic solution is a method designed to identify pathogens or infections without requiring conventional microbial culture techniques. These solutions utilize advanced technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays to rapidly pinpoint pathogens directly from patient samples such as blood, saliva, or tissue. For instance, in April 2024, Deepull Diagnostics S.L., a Spain-based manufacturing company, launched the UllCORE diagnostic system for early sepsis detection. The UllCORE system is a benchtop, culture-free multiplex PCR platform developed by Deepull for rapid pathogen identification in sepsis and other acute infections. It extracts microbial DNA from 8 mL of whole blood and provides 50 reportable results within one hour. The system detects 95% of sepsis-causing pathogens, including bacteria, fungi, and antibiotic resistance genes. Designed to improve early diagnosis and reduce antibiotic misuse, UllCORE supports hospitals combating antimicrobial resistance.
Who Are The Top-Performing Companies In The Sepsis Diagnostics Market In Recent Years?
Major companies operating in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMérieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., EKF Diagnostics Holdings plc, Boditech Med Inc., Alifax S.r.l., Abionic SA
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/sepsis-diagnostics-global-market-report
Which Region Currently Holds The Largest Share Of The Sepsis Diagnostics Market?
North America was the largest region in the sepsis diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Sepsis Diagnostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23514&type=smp
Browse Through More Reports Similar to the Global Sepsis Diagnostics Market 2026, By The Business Research Company
Gastrointestinal Pathogen Testing Market Report 2026
Infectious Disease Diagnostics Testing Market Report 2026
Hemostasis Diagnostic Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
